Ilaria Proietti, Nicoletta Bernardini, Nevena Skroza, Alessandra Mambrin, Ersilia Tolino, Anna Marchesiello, Federica Marraffa, Giovanni Rossi, Salvatore Volpe, Concetta Potenza
{"title":"PSSD and Biologic Therapy: Real-Life Data in 417 Patients with Moderate to Severe Psoriasis.","authors":"Ilaria Proietti, Nicoletta Bernardini, Nevena Skroza, Alessandra Mambrin, Ersilia Tolino, Anna Marchesiello, Federica Marraffa, Giovanni Rossi, Salvatore Volpe, Concetta Potenza","doi":"10.2174/1574887117666220623161751","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Psoriasis is a chronic relapsing immune-mediated disease leading to a strong impact on patient's quality of life. The treatment of psoriasis has undergone a revolution with the advent of biological therapies. Currently, Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) scores are in use to assess the overall severity of pathology. A new self-administered questionnaire, the Psoriasis Symptoms and Signs Diary (PSSD), assesses the severity of six psoriasis symptoms (itch, skin tightness, burning, stinging, and pain,) and five signs (dryness, cracking, scaling, shedding/flaking, redness, and bleeding).</p><p><strong>Objective: </strong>To evaluate and compare the efficacy of biologic therapies through PSSD in patients with moderate to severe psoriasis.</p><p><strong>Methods: </strong>The PSSD questionnaire was administered to all the patients at the beginning and after 6 months of biologic therapy (anti-TNFalpha, anti-IL17, anti-IL23, anti-IL12/23 and phhosphodiesterase-4 Inhibitors).</p><p><strong>Results: </strong>The study population included 417 adult patients with moderate to severe psoriasis in treatment with biologic drugs. All the drugs contributed to a significant improvement in mean total PSSD at t 24; anti-IL17 and anti-IL23 led to a significantly greater reduction at t 24 mean PSSD when compared to other therapies.</p><p><strong>Conclusion: </strong>The PSSD, is a new validated instrument useful for capturing psoriasis patient's quality of life and evaluating treatment efficacy. In our study, this score has been useful to put in evidence significant differences between biological drugs.</p>","PeriodicalId":1,"journal":{"name":"Accounts of Chemical Research","volume":" ","pages":"171-176"},"PeriodicalIF":17.7000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Accounts of Chemical Research","FirstCategoryId":"92","ListUrlMain":"https://doi.org/10.2174/1574887117666220623161751","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Psoriasis is a chronic relapsing immune-mediated disease leading to a strong impact on patient's quality of life. The treatment of psoriasis has undergone a revolution with the advent of biological therapies. Currently, Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) scores are in use to assess the overall severity of pathology. A new self-administered questionnaire, the Psoriasis Symptoms and Signs Diary (PSSD), assesses the severity of six psoriasis symptoms (itch, skin tightness, burning, stinging, and pain,) and five signs (dryness, cracking, scaling, shedding/flaking, redness, and bleeding).
Objective: To evaluate and compare the efficacy of biologic therapies through PSSD in patients with moderate to severe psoriasis.
Methods: The PSSD questionnaire was administered to all the patients at the beginning and after 6 months of biologic therapy (anti-TNFalpha, anti-IL17, anti-IL23, anti-IL12/23 and phhosphodiesterase-4 Inhibitors).
Results: The study population included 417 adult patients with moderate to severe psoriasis in treatment with biologic drugs. All the drugs contributed to a significant improvement in mean total PSSD at t 24; anti-IL17 and anti-IL23 led to a significantly greater reduction at t 24 mean PSSD when compared to other therapies.
Conclusion: The PSSD, is a new validated instrument useful for capturing psoriasis patient's quality of life and evaluating treatment efficacy. In our study, this score has been useful to put in evidence significant differences between biological drugs.
期刊介绍：
Accounts of Chemical Research presents short, concise and critical articles offering easy-to-read overviews of basic research and applications in all areas of chemistry and biochemistry. These short reviews focus on research from the author’s own laboratory and are designed to teach the reader about a research project. In addition, Accounts of Chemical Research publishes commentaries that give an informed opinion on a current research problem. Special Issues online are devoted to a single topic of unusual activity and significance.
Accounts of Chemical Research replaces the traditional article abstract with an article "Conspectus." These entries synopsize the research affording the reader a closer look at the content and significance of an article. Through this provision of a more detailed description of the article contents, the Conspectus enhances the article's discoverability by search engines and the exposure for the research.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
